Sir, Response to Vallance
In response to Dr Vallance's letter, 1 we refute the implication that this article 2 is an example of 'medical ghostwriting'. Alpha-Plus Medical Communications acts in accordance with good publication practice guidelines (GPP2) as published in the BMJ, 3 and confirms that there was no exception with this article. The authors provided direction, had full control of the editorial content, and accepted full responsibility for views and opinions as well as accuracy of the content. 4 A clear and unambiguous statement regarding our involvement in this publication was included in the acknowledgements.
In relation to Dr Vallance's claim that Alpha-Plus provides 'complete medical communication services for all marketing needs', we would like to highlight that the source of this statement is an out-of-date and obsolete business listing from early 2009. We thank Dr Vallance for drawing our attention to this listing and have requested that it is removed at the earliest opportunity. Please refer your reader to our website (http:// www.fishawack.com) for up-to-date and accurate information regarding our group of companies. As you will note on our website, publication activities are separate from other medical communications services.
We would like to add that with regard to comments made about the appointment of Jo Jarvis, the conference in which Jo participated focused on how the industry should interact with different stakeholder groups (including physicians) in an ethically responsible manner and in compliance with the latest code of practice governing this area. 
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Our patient had a rapid and dramatic response after commencing and discontinuing tadalafil. This case could be an event of association, but could also be cause and effect, as explained below. PDE-5 inhibitors modify retinal and choroidal blood flow by their pharmacological effects on the PDE-5 enzyme, which is expressed on retinal and choroidal vasculature. This mechanism involving slowing of choroidal blood flow is also seen in the pathogenesis of CSCR. 2 The resultant increased hydrostatic pressure within the choroid affects the ability of the overlying RPE to pump fluid from the retina to the choroid. 3 A recent randomised controlled trial showed that when tadalafil was used in therapeutic doses daily for 6 months, there was no adverse significant effect on visual function or ocular anatomy. 4 Tadalafil may be used once daily or as needed in doses of 2.5-20 mg. Our patient admitted to taking repeated doses larger than 20 mg to achieve a more desired erectile effect.
This case report highlights that patients should be advised not to exceed the maximum dose of tadalafil. This case also reminds us that patients with CSCR need to be asked a thorough drug history (including recreational drugs); this is perhaps overlooked in this group, who are usually healthy and young. 
